AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02734212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treatment as Usual
Description: The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
Study NCT00167674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined short-course zidovudine/nevirapine
Description: 300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight > 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.
Study NCT00167674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: 300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
Study NCT00496665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Taken orally once a day in 28-day cycles (the dose will vary)
Study NCT00496665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
Study NCT00496665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
Study NCT02978274 — intervention group
Intervention type: DRUG
Intervention: MMF
Description: MMF withdrawal by engraftment post haplo-SCT
Study NCT02978274 — intervention group
Intervention type: DRUG
Intervention: MMF
Description: MMF withdrawal by 2 month post haplo-SCT
Study NCT02096653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-ray SI joint steroid injection
Description: Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
Study NCT02096653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-guided SI steroid injection
Description: Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
Study NCT00242112 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Prostate
Study NCT03680599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connection to Health for Smokers
Description: Connection to Health for Smokers includes 5 core components supported by online tools: (1) comprehensive electronic patient survey, (2) automated summary report to flag areas of difficulty (3) interactive priority setting, (4) interactive action planning, and (5) electronic text reminders and followup.
Study NCT03680599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Participants will complete a survey and receive standard one-on-one smoking cessation according to a usual care protocol delivered by health educators
Study NCT02573519 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 11C Donepezil PET/CT scan
Description: Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) \[11C\]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
Study NCT02573519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D-Transit
Description: 3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:~1. A wireless electromagnetic capsule to be swallowed by the subject~2. A portable detector plate comprising four sensors worn in a belt around the waist~3. Specific software for visualizing and analyzing data
Study NCT04022057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5
Description: Sham Injection
Study NCT01672502 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep health education provided via a web-based program
Description: All firefighters in the experimental group and controls will be asked to complete an approximately 30 minute education session. This education session will split into two modules, module 1: an introduction to the program along with basic sleeps hygiene information and module 2: standard training. Topics covered in module 2 will include basic sleep physiology, the causes and consequences of sleep disorders, and fatigue countermeasures. We will emphasize strategies to maximize sleep and reduce fatigue both on and off work.
Study NCT00881959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puros® Dermis versus Alloderm®
Description: Puros Dermis and Alloderm (both Allograft Tissue Matrix)
Study NCT00881959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puros® Dermis versus Alloderm®
Description: Puros Dermis and Alloderm (both Allograft Tissue Matrix)
Study NCT03013166 — intervention group
Intervention type: OTHER
Intervention: Corticosteroid medication
Description: Patients will be grouped into Cohort 1 (IR hydrocortisone), cohort 2 (IR prednisolone), cohort 3 (MR hydrocortisone), or cohort 4 (IR to MR hydrocortisone) depending on which oral corticosteroid medications were received during the observation period.
Study NCT01672502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep health education provided via a web-based program
Description: All firefighters in the experimental group and controls will be asked to complete an approximately 30 minute education session. This education session will split into two modules, module 1: an introduction to the program along with basic sleeps hygiene information and module 2: standard training. Topics covered in module 2 will include basic sleep physiology, the causes and consequences of sleep disorders, and fatigue countermeasures. We will emphasize strategies to maximize sleep and reduce fatigue both on and off work.
Study NCT01672502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep disorder detection and treatment
Description: Firefighters in the intervention districts will complete a sleep disorders screening questionnaire. The questionnaire will focus on identifying individuals who show increased likelihood of suffering from obstructive sleep apnea, insomnia, shift work disorder, and restless legs syndrome using validated screening tools. Those assessed to be at high risk for one of these sleep disorders will be referred to a local AASM-accredited Clinical Sleep Disorders Service for evaluation and, if necessary, treatment. Diagnosis and treatment of sleep-related disorders will reduce the risk of fatigue-related accidents and improve the health and safety of affected individuals.
Study NCT01672502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep disorder detection and treatment
Description: Firefighters in the intervention districts will complete a sleep disorders screening questionnaire. The questionnaire will focus on identifying individuals who show increased likelihood of suffering from obstructive sleep apnea, insomnia, shift work disorder, and restless legs syndrome using validated screening tools. Those assessed to be at high risk for one of these sleep disorders will be referred to a local AASM-accredited Clinical Sleep Disorders Service for evaluation and, if necessary, treatment. Diagnosis and treatment of sleep-related disorders will reduce the risk of fatigue-related accidents and improve the health and safety of affected individuals.
Study NCT01672502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimization of Sleep in Fire Station
Description: First, we will review and retrofit the sleeping quarters to provide a better environment for napping and sleep; light, noise, bed type, space, temperature, and location would all be considered and where possible, changes made to improve the sleeping environment. Secondly, we will work with management and union personnel to develop a 'sleep friendly' policy during the daytime, with specified protected times for naps during the day before the overnight work in order to reduce sleepiness during overnight work. Finally, we will upgrade the alerting systems, that is, we will work with management and union personnel to consider changing the policy that requires the sleeping areas of all stations to receive all alarm calls, even if that particular station is not required to attend the alarm.
Study NCT04671420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX01
Description: Patients will receive HLX01 intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
Study NCT04671420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mabthera®
Description: Patients will receive Mabthera® intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
Study NCT03124368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).
Study NCT03945227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001
Description: drug: standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
Study NCT03945227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001
Description: drug:PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. -For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
Study NCT01155908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Besylate / Benazepril Hydrochloride
Description: 10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
Study NCT01155908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate / Benazepril Hydrochloride
Description: 10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
Study NCT00687726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing balance exercise
Description: Standing balance and mini squat exercise performed 30 times/day/side, 5 days/week, for 4 weeks.
Study NCT00687726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Isometric knee extension exercise
Description: Isometric knee extension exercise performed 10 repetitions/set, 3 sets/day, 5 days/week for 4 weeks
Study NCT03863535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: Participants were randomized (1:1) to receive IVC+PRP or PRP monotherapy. Patients in IVC+PRP group with diabetic macular edema (DME) received 3 monthly IVC injections along with standard PRP within 1 week after the first injection. Those without DME received 1 lVC injection and standard PRP within 1 week after the injection . Re-treatments in both groups were at the investigators'discretion.
Study NCT03863535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal coagulation
Description: The PRP monotherapy group received standard PRP between day 1 and month 2; thereafter, re-treatments in both groups were at the investigators'discretion.
Study NCT03863535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal coagulation
Description: The PRP monotherapy group received standard PRP between day 1 and month 2; thereafter, re-treatments in both groups were at the investigators'discretion.
Study NCT02074358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT02277873 — intervention group
Intervention type: BEHAVIORAL
Intervention: pregnancy
Description: Observational study in order to establish relationship between moon and births
Study NCT03205384 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Study NCT03016559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: releasing muscle
Description: At baseline, hip and knee angles were measured. The quadratus lumborum muscle was released. After that, the hip and knee angles were re-measured.
Study NCT00160030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX 4
Description: total treatment of six 2-weekly cycles of FOLFOX 4, the first 3 cycles starting on D1, D15 and D29 concomitant with 5 weeks' radiotherapy.
Study NCT00160030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU / Cisplatin
Description: two cycles of 5-FU / Cisplatin on week 1 and 5 of radiotherapy and two cycles of chemotherapy with 5-FU / Cisplatin on week 8 and 11 (one cycle each three weeks after the end of radiotherapy).
Study NCT03474705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eccentric Training Protocol
Description: A custom-built dynamic shoulder dynamometer (Aalborg University, Aalborg, Denmark) will be used. Participants will be seated with back support and no feet support. The maximal voluntary contraction (MVC) of the painful side will be assessed. Sessions will start with a 5-min warm-up. After that, participants will sit in the dynamometer, and the range of shoulder elevation (highest and lowest vertical position) will be measured for the affected side. During training, subjects will have to counteract a dynamometer vertical force from the highest to the lowest shoulder position at a force equal to 60% (training sessions 1-3), 70% (training sessions 4-6), and 80% (training sessions 7-10) of the MVC recorded during baseline. Three bouts of 10 repetitions (sessions 1-3), 8 repetitions (sessions 4-6) and 6 repetitions (sessions 7-10) will be performed, with a 3-second rest between contractions and a 2-minute break between bouts.
Study NCT02826603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: 300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
Study NCT02826603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
Study NCT02074358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cofact (4-Factor PCC)
Study NCT02074358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beriplex P/N (4-Factor PCC)
Study NCT02074358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Saline solution)
Study NCT04316429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg included vegan phase
Description: : Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets. Participants will also receive instructions to preserve an isocaloric condition with the addition of 2 eggs in their diets. Counseling of the study participants will be based on the U.S. Department of Agriculture (USDA) healthy vegetarian meal plans, with modifications to exclude dairy products. \[21\] Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet (with the exception of including eggs) will also be provided.
Study NCT04316429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vegan Phase
Description: The participants will consume a vegan diet for 6 weeks. The study dietitian will provide counseling and sample meal plans based on the USDA healthy vegetarian dietary pattern, with modifications to exclude eggs and dairy products. Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet will also be provided.
Study NCT02231567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Rehabilitation
Description: The patients will be treated in inpatient clinic with a neurocognitive rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
Study NCT02231567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Rehabilitation
Description: The patients will be treated in inpatient clinic with a traditional rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
Study NCT00736164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenomethionine
Description: Given orally
Study NCT00736164 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01168232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV
Study NCT01168232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00827008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane mesylate
Description: Up-titration treatment period of 5 weeks up to 75mg Neramexane mesylate oral per day followed by 49 weeks treatment maintenance
Study NCT00003102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
Description: cG250 is an IgG1 chimeric monoclonal antibody. It was supplied as a sterile solution at a concentration of 1.0 mg/mL in either a 2 mL or a 5 mL vial. cG250 was radiolabeled with Iodine-131 prior to use.
Study NCT02573519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3D-Transit during treatment with Pyridostigmine
Description: 3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
Study NCT01273103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg [14C]- GSK2248761
Description: single oral suspension dose of \[14C\]- GSK2248761 200 mg
Study NCT02393196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)
Description: Before spinal anesthesia
Study NCT01095562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 Dose 1, ABT-126 Dose 2
Study NCT01095562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02573519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D-Transit after Malone appendicostomy
Description: 3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
Study NCT03839953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Program
Description: This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.
Study NCT03839953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Therapy
Description: After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.